Literature DB >> 2437327

Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins.

D D Ho, M G Sarngadharan, M S Hirsch, R T Schooley, T R Rota, R C Kennedy, T C Chanh, V L Sato.   

Abstract

Serum neutralizing antibodies against the human immunodeficiency virus were frequently detected in infected individuals, and low or absent serum neutralizing titers correlated with poor prognosis. Multiple diverse human immunodeficiency virus isolates were found to exhibit similar susceptibility to neutralization by a panel of human seropositive sera, suggesting that neutralizing antibodies are largely directed against conserved viral domains. Furthermore, utilizing antisera raised against a library of synthetic env peptides, four regions which are important in the neutralization process have been identified within both human immunodeficiency virus envelope glycoproteins (gp41 and gp120). Three of these are in conserved domains and should be considered for inclusion in a candidate vaccine.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2437327      PMCID: PMC254212     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  28 in total

1.  Immunological properties of the Gag protein p24 of the acquired immunodeficiency syndrome retrovirus (human T-cell leukemia virus type III).

Authors:  M G Sarngadharan; L Bruch; M Popovic; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1985-05       Impact factor: 11.205

2.  Complete nucleotide sequence of the AIDS virus, HTLV-III.

Authors:  L Ratner; W Haseltine; R Patarca; K J Livak; B Starcich; S F Josephs; E R Doran; J A Rafalski; E A Whitehorn; K Baumeister
Journal:  Nature       Date:  1985 Jan 24-30       Impact factor: 49.962

3.  Nucleic acid structure and expression of the human AIDS/lymphadenopathy retrovirus.

Authors:  M A Muesing; D H Smith; C D Cabradilla; C V Benton; L A Lasky; D J Capon
Journal:  Nature       Date:  1985 Feb 7-13       Impact factor: 49.962

4.  HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex.

Authors:  M Robert-Guroff; M Brown; R C Gallo
Journal:  Nature       Date:  1985 Jul 4-10       Impact factor: 49.962

5.  Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients.

Authors:  R A Weiss; P R Clapham; R Cheingsong-Popov; A G Dalgleish; C A Carne; I V Weller; R S Tedder
Journal:  Nature       Date:  1985 Jul 4-10       Impact factor: 49.962

6.  Immunological properties of HTLV-III antigens recognized by sera of patients with AIDS and AIDS-related complex and of asymptomatic carriers of HTLV-III infection.

Authors:  M G Sarngadharan; F diMarzo Veronese; S Lee; R C Gallo
Journal:  Cancer Res       Date:  1985-09       Impact factor: 12.701

7.  Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patients with neurologic syndromes related to the acquired immunodeficiency syndrome.

Authors:  D D Ho; T R Rota; R T Schooley; J C Kaplan; J D Allan; J E Groopman; L Resnick; D Felsenstein; C A Andrews; M S Hirsch
Journal:  N Engl J Med       Date:  1985-12-12       Impact factor: 91.245

8.  Characterization of gp41 as the transmembrane protein coded by the HTLV-III/LAV envelope gene.

Authors:  F D Veronese; A L DeVico; T D Copeland; S Oroszlan; R C Gallo; M G Sarngadharan
Journal:  Science       Date:  1985-09-27       Impact factor: 47.728

9.  Genomic diversity of human T-lymphotropic virus type III (HTLV-III).

Authors:  F Wong-Staal; G M Shaw; B H Hahn; S Z Salahuddin; M Popovic; P Markham; R Redfield; R C Gallo
Journal:  Science       Date:  1985-08-23       Impact factor: 47.728

10.  Detection of human anti-HTLV-III antibodies by indirect immunofluorescence using fixed cells.

Authors:  E G Sandstrom; R T Schooley; D D Ho; R Byington; M G Sarngadharan; M E MacLane; M Essex; R C Gallo; M S Hirsch
Journal:  Transfusion       Date:  1985 Jul-Aug       Impact factor: 3.157

View more
  99 in total

1.  Evidence against extracellular exposure of a highly immunogenic region in the C-terminal domain of the simian immunodeficiency virus gp41 transmembrane protein.

Authors:  Thomas S Postler; José M Martinez-Navio; Eloísa Yuste; Ronald C Desrosiers
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

Review 2.  Cellular and humoral antigenic epitopes in HIV and SIV.

Authors:  D F Nixon; K Broliden; G Ogg; P A Broliden
Journal:  Immunology       Date:  1992-08       Impact factor: 7.397

3.  Examination of sera from human immunodeficiency virus type 1 (HIV-1)-infected individuals for antibodies reactive with peptides corresponding to the principal neutralizing determinant of HIV-1 gp120 and for in vitro neutralizing activity.

Authors:  R Q Warren; S A Anderson; W M Nkya; J F Shao; C W Hendrix; G P Melcher; R R Redfield; R C Kennedy
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

4.  Characterization of the cDNA of a broadly reactive neutralizing human anti-gp120 monoclonal antibody.

Authors:  W A Marasco; J Bagley; C Zani; M Posner; L Cavacini; W A Haseltine; J Sodroski
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

5.  Neutralizing antibodies modulate replication of simian immunodeficiency virus SIVmac in primary macaque macrophages.

Authors:  M F McEntee; M C Zink; M G Anderson; H Farzadegan; R J Adams; K A Kent; E J Stott; J E Clements; O Narayan
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

6.  Generation of hybrid genes and proteins by vaccinia virus-mediated recombination: application to human immunodeficiency virus type 1 env.

Authors:  L Gritz; A Destree; N Cormier; E Day; V Stallard; T Caiazzo; G Mazzara; D Panicali
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

7.  Selection of genetic variants of simian immunodeficiency virus in persistently infected rhesus monkeys.

Authors:  D P Burns; R C Desrosiers
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

8.  Evidence for non-V3-specific neutralizing antibodies that interfere with gp120/CD4 binding in human immunodeficiency virus 1-infected humans.

Authors:  C Y Kang; P Nara; S Chamat; V Caralli; T Ryskamp; N Haigwood; R Newman; H Köhler
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-15       Impact factor: 11.205

9.  Characterization of in vitro inhibition of human immunodeficiency virus by purified recombinant CD4.

Authors:  R A Byrn; I Sekigawa; S M Chamow; J S Johnson; T J Gregory; D J Capon; J E Groopman
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

10.  B- and T-lymphocyte responses to an immunodominant epitope of human immunodeficiency virus.

Authors:  R D Schrier; J W Gnann; A J Langlois; K Shriver; J A Nelson; M B Oldstone
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.